Track topics on Twitter Track topics that are important to you
Proteome Sciences Plc Proteome Sciences is a life sciences company that delivers content for personalized medicine in various areas such as biomarker assays, isobaric and isotopic reagents, biomarker services and proprietary biomarkers. The company specializes in providing proteomics and peptidomics services and applications, and mass spectrometry protein analysis capability. It offers PS Biomarker Services under which it provides integrated proteomic services for the discovery, validation and measurement in clinical trials and in vitro diagnostics of biomarkers. The company develops novel biomarkers for various disease areas such as central nervous system diseases including Alzheimer's, Huntington's, stroke and traumatic brain injury; oncology comprising lung, breast, colorectal and esophageal cancers; and cardiac diseases, for diagnostic and treatment applications. It has facilities in London and Frankfurt. Proteome Sciences is headquartered in Cobham, the UK.
This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Proteome Sciences Plc
The report provides pipeline analysis on all pipeline products of the company by equipment type, by indication, by development stage, and by trial status
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indications, applications and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials wherever applicable with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research Development strategies
Develop marketentry and market expansion strategies
Exploit inlicensing and outlicensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next highvalue products that your competitor would add in its portfolio
Immunoassay - ELISA
Immunoassays are quick and accurate tests to detect specific molecules. Immunoassays rely on an antibody to bind to the specific structure of a molecule. Antibodies are proteins generated by animals in response to the invasion of a foreign molecule (anti...
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...